LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.96
+2.23%Aug 11, 2026, 20:05 UTC
LENZ Therapeutics reported its second quarter 2026 financial results, with total revenue of $5.5 million from VIZZ product sales and global license agreements.
Jul 6, 2026, 12:15 UTC
LENZ Therapeutics launched a new telehealth prescribing option for VIZZ to treat presbyopia.
Source:Jun 24, 2026, 12:30 UTC
LENZ Therapeutics and Arrotex Pharmaceuticals entered into an exclusive license and commercialization agreement for VIZZ in Australia and New Zealand.
Source:Jun 8, 2026, 15:35 UTC
LENZ Therapeutics granted Everest Medicines the rights to develop and commercialize its presbyopia drug VIZZ (LNZ100) in Greater China.
Source: